- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03923075
Dexmetomidine in Children Undergoing General Anaesthesia
The Effects of Dexmedetomidine on Induction of Anaesthesia and Onset of Neuromuscular Blockade in Children
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Children 4 to 12 years old, ASA I-II, scheduled for elective minor or medium procedure under general anaesthesia will be included in the study, after written informed concern from their parents has been obtained. Participants will be randomly allocated according to the type of the solution infused 10 minutes before the induction of general anaesthesia into one of the following two groups using the closed envelop method.
DEX group: patients will receive 0.5μcg/kg IV bolus of dexmedetomidine in 10 min, right before the induction of general anaesthesia. The concentration of dexmedetomidine solution is 0.2μcg/ml, (100μcg of dexmedetomidine are diluted in 50ml N/S 0.9%), which corresponds to volume (ml) calculated by the type: "body weight (Kg)/4 or body weight (Kg) X 0.25".
Placebo group: patients will receive N/S 0.9% IV in 10 min, right before the induction of general anaesthesia. The volume infused (ml) is determined by the same type: "body weight (Kg)/4 or body weight (Kg) X 0.25".
The above solutions will be prepared by the anaesthetist who will provide the anaesthesia and will not be known to the anaesthetist who will record the study's measurements.
No premedication will be given. All children will receive the same anaesthesia induction scheme.
Once the patients have entered the operating theater, standard monitoring will be applied (NIBP, ECG, SpO2) and an IV line will be inserted. Depth of anaesthesia and monitoring of neuromuscular blockade will be recorded by BIS and TOF, respectively. Afterwards continues infusion of dexmedetomidine or N/S 0.9% will be initiated, depending on the assigned group, for duration of 10 min.
Right after the end of the infusion, we will proceed to the induction of anaesthesia with 3mg/kg of propofol and 2μcg/kg of fentanyl and when BIS<60 will be achieved, rocuronium will be administered at a dose of 0.7 mg/kg . Right afterwards, neuromuscular blockade will be estimated using the TOF acceleromyography (4 supramaximal twitches, 0.5sec interval in 2sec, frequency 2Hz, intensity 50mA). TOF will be repeated every 15sec. At the same time, ventilation of the patient will be supported with a bag and mask (Ο2 100%). When TOF=0 will be achieved, the patient will be intubated. After intubation, anaesthesia will be maintained with sevoflurane 1 MAC in 50% O2/Air.
The intubation conditions will be estimated using the Viby-Mogensen score (scale of 5 parameters). Also, number of intubation attempts will be recorded.
The study period is from "right before the start" of the dexmedetomidine or the N/S 0.9% infusion up to 5 min after the tracheal intubation. The following time points will be recorded:
Start time of the IV infusion of dexmedetomidine or N/S 0.9% (tstart) End time of the IV infusion of dexmedetomidine or N/S 0.9% (tend) Time of propofol injection (tprop) Time of achieving BIS<60 (tBIS<60) Time from propofol injection to achieve BIS<60 (tprop - tBIS<60) in min Time of rocuronium injection (troc) Time of achieving TOF=0 (tTOF=0) Time from rocuronium injection to TOF=0 (troc - tTOF=0) in min Time that intubation performed (tintubation)
Measurements Heart rate (HR), systolic arterial pressure (SAP), SpO2 and BIS will be recorded at the following time points: just before the start of infusion of dexmedetomidine or N/S 0.9% (tbaseline) and afterwards every 3 min during the infusion, as well as at the particular time points tend, tprop, tBIS<60, troc, tTOF=0, tintubation and 5 min after the intubation. Viby-Mogensen score and number of intubation attempts will also be recorded.
During the study period, any adverse effects or incidences like respiratory depression during the 10 min infusion of the study solutions, bradycardia (defined as >20% reduction of HR from the baseline values or as HR<60bpm), hypotension (defined as >20mmHg reduction of SAP from the baseline values), allergic reactions, bronchospasm and laryngospasm will be recorded. In case of bradycardia or hypotension, IV atropine 0.02μcg/kg or ephedrine 1-2μcg/kg will be administered, respectively. In case of persistent bradycardia despite the use of atropine, dexmedetomidine infusion will be stopped and the child will be excluded from the study.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Attiki
-
Athens, Attiki, Grecia, 12462
- 2nd Department of Anesthesiology, Attikon University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- children underoing elective surgery under general anaesthsia
- age 4-12 years old
- ASA I-II
Exclusion Criteria:
- patient or parent refusal
- Mallampati score> 3
- BMI>35
- severe systemic cardiac disease
- neuromuscular disease
- recent respiratory infection
- drug allergy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Dexmedetomidine
Drug: dexmedetomidine (Dexmed) solution(100μcg of dexmedetomidine in 50ml N/S 0.9%). given at a bolus dose of 0.5μcg/kg of the dexmedetomidine solution [that corresponds to the volume (ml) calculated by the type "body weight (Kg)/4 or body weight (Kg) X 0.25". THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY |
INFUSION BEFORE INDUCTION OF ANAESTHESIA
Altri nomi:
|
Comparatore placebo: 0.9 % saline
Drug:0.9 % saline solution (Normal saline) given at a volume (ml) determined by the type: "body weight (Kg)/4 or body weight (Kg) X 0.25" THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY
|
INFUSION BEFORE INDUCTION OF ANAESTHESIA
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Onset of neuromuscular blockade
Lasso di tempo: Up to 5 minutes after the injection of rocuronium
|
Neuromuscular blockade is estimated with TOF acceleromyography, while onset of neuromuscular blockaded is defined as the time needed to achieve TOF=0 after the injection of rocuronium.
|
Up to 5 minutes after the injection of rocuronium
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Onset of anaesthesia induction
Lasso di tempo: Up to 15 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively
|
The depth of anaesthesia is monitored using the BIS device (range 0-100).
Onset of anesthesia is defined as the time needed to achieve BIS value<60, after the injection of propofol.
|
Up to 15 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively
|
Number of participants who developed bradycardia
Lasso di tempo: Up to 30 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively
|
Bradycardia is defined as >20% reduction of HR from the baseline values or as HR<60bpm using ECG monitoring.
|
Up to 30 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively
|
Number of participants who developed hypotension
Lasso di tempo: Up to 30 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively
|
Hypotension is defined as >20mmHg reduction of SAP from the baseline values using noninvasive monitoring of arterial pressure
|
Up to 30 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively
|
Collaboratori e investigatori
Sponsor
Investigatori
- Cattedra di studio: Georgia K Kostopanagiotou, 2nd Department of Anaesthesiology, "Attikon" University Hospital
- Investigatore principale: Paraskevi K Matsota, 2nd Department of Anaesthesiology, "Attikon" University Hospital
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Effetti fisiologici delle droghe
- Agenti adrenergici
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Depressori del sistema nervoso centrale
- Agenti del sistema nervoso periferico
- Analgesici
- Agenti del sistema sensoriale
- Analgesici, non narcotici
- Agonisti del recettore adrenergico alfa-2
- Alfa-agonisti adrenergici
- Agonisti adrenergici
- Ipnotici e sedativi
- Dexmedetomidina
Altri numeri di identificazione dello studio
- DEXAINMBCH
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .